BridgeBio Oncology Registers 63M Shares Post-Merger, Eyes KRAS Data H2 2025

TL;DR

**BBOT's S-1 filing for 63 million shares by selling securityholders signals potential dilution and near-term price volatility, despite promising oncology pipeline data expected in H2 2025.**

AI Summary

BridgeBio Oncology Therapeutics, Inc. (BBOT) is a clinical-stage biotechnology company focused on developing therapies for cancers driven by RAS and PI3K mutations. The company's pipeline includes three orally bioavailable small molecule inhibitors. Its lead candidate, BBO-8520, is a dual KRAS G12C "ON/OFF" inhibitor currently in the dose escalation phase of the ONKORAS-101 trial for metastatic KRAS G12C mutant NSCLC. BBOT anticipates sharing initial interim data from ONKORAS-101 in the second half of 2025. Another key candidate, BBO-10203, is a RAS:PI3K Breaker designed to inhibit PI3Ka signaling in tumors by targeting the RAS-binding domain of PI3K, aiming to avoid hyperglycemia and hyperinsulinemia side effects observed with previous PI3K inhibitors. The company recently completed a Business Combination on August 11, 2025, with Helix Acquisition Corp. II, resulting in BBOT becoming a Delaware corporation and its common stock listed on Nasdaq under "BBOT". This S-1 filing registers 63,054,549 shares of common stock for sale by selling securityholders, including 24,343,711 PIPE Shares from a February 28, 2025 financing, and 1,907,207 shares issuable upon option exercise with prices ranging from $1.02 to $7.88.

Why It Matters

This S-1 filing signals BridgeBio Oncology Therapeutics' transition to a publicly traded entity following its Business Combination with Helix Acquisition Corp. II, allowing existing securityholders to sell a substantial 63,054,549 shares. For investors, this could introduce significant selling pressure on the Nasdaq-listed BBOT stock, which closed at $9.45 on August 28, 2025. The company's focus on KRAS and PI3K-driven cancers places it in a highly competitive and lucrative oncology market, with its BBO-8520 candidate directly competing with first-generation KRAS G12C inhibitors. The success or failure of its clinical trials, particularly the upcoming ONKORAS-101 interim data, will be critical for its valuation and future growth, impacting employees, customers, and the broader oncology treatment landscape.

Risk Assessment

Risk Level: high — The risk level is high due to the substantial number of shares, 63,054,549, being registered for sale by selling securityholders, which could create significant downward pressure on the stock price. Furthermore, as a clinical-stage biotechnology company, BBOT faces inherent high risks associated with drug development, including the uncertainty of clinical trial outcomes for BBO-8520 and BBO-10203, and the potential for adaptive resistance to its therapies, as noted for first-generation KRAS G12C inhibitors.

Analyst Insight

Investors should exercise caution given the potential for significant selling pressure from the 63,054,549 registered shares. Monitor the upcoming interim data from the ONKORAS-101 trial in H2 2025 closely, as positive results could mitigate some selling pressure and validate the company's pipeline, but be prepared for volatility.

Financial Highlights

debt To Equity

Not specified

revenue

$0

operating Margin

Not specified

total Assets

Not specified

total Debt

Not specified

net Income

Not specified

eps

Not specified

gross Margin

Not specified

cash Position

Not specified

revenue Growth

N/A

Executive Compensation

Key Numbers

• 63,054,549 — Shares of Common Stock (Total shares registered for sale by Selling Securityholders, indicating potential market overhang.)
• 24,343,711 — PIPE Shares (Shares issued in a private placement on February 28, 2025, part of the registered shares.)
• 4,648,186 — Shares of Common Stock (Issued to the Sponsor and initial shareholders of Helix in connection with the Business Combination.)
• 32,155,445 — Shares of Common Stock (Issued or issuable to certain equity holders of the Company pursuant to the Business Combination.)
• 1,907,207 — Shares of Common Stock (Issuable upon exercise of stock options, with exercise prices ranging from $1.02 to $7.88 per share.)
• $1.02 to $7.88 — Option Exercise Price Range (Range for the 1,907,207 shares issuable upon exercise of stock options.)
• August 11, 2025 — Closing Date (Date of the Business Combination between Helix and TheRas.)
• February 28, 2025 — Business Combination Agreement Date (Initial date of the agreement for the Business Combination.)
• August 28, 2025 — Closing Price Date (Date when BBOT's common stock closed at $9.45 per share on Nasdaq.)
• 30% — Prevalence of RAS mutations (Approximate percentage of all human cancers driven by RAS mutations.)

Key Players & Entities

• BridgeBio Oncology Therapeutics, Inc. (company) — Registrant and clinical-stage biotechnology company
• Eli Wallace (person) — Chief Executive Officer of BridgeBio Oncology Therapeutics, Inc.
• Maggie L. Wong (person) — Counsel at Goodwin Procter LLP
• Jocelyn M. Arel (person) — Counsel at Goodwin Procter LLP
• Helix Acquisition Corp. II (company) — Pre-Business Combination entity, now BridgeBio Oncology Therapeutics, Inc.
• TheRas, Inc. (company) — Pre-Business Combination entity, now a wholly-owned subsidiary of BBOT
• SEC (regulator) — Securities and Exchange Commission
• Nasdaq Global Market (regulator) — Stock exchange where BBOT is listed
• Helix Holdings II LLC (company) — Sponsor of Helix Acquisition Corp. II
• $9.45 (dollar_amount) — Closing price of BBOT Common Stock on August 28, 2025

FAQ

Risk Factors

• Reliance on Key Personnel [high — operational]: The company's success is heavily dependent on its key scientific and management personnel, including its CEO Neil Desai. The loss of any of these individuals could materially and adversely affect its ability to execute its business strategy and develop its product candidates.
• Clinical Trial Failures and Delays [high — regulatory]: BridgeBio Oncology Therapeutics has a limited operating history and no products approved for commercial sale. Its product candidates are in various stages of clinical development, and there is no guarantee that any of them will successfully complete clinical trials or receive regulatory approval. Delays or failures in clinical trials, such as the ongoing ONKORAS-101 trial for BBO-8520, could significantly impact the company's future prospects.
• Substantial Future Capital Requirements [high — financial]: The company anticipates that it will continue to incur substantial operating losses and will require substantial additional funding to fund its ongoing operations, clinical trials, and potential commercialization of its product candidates. The ability to secure this funding through equity or debt financings, or strategic partnerships, is critical.
• Intense Competition [medium — market]: The biotechnology industry is characterized by rapid and significant technological advances and a large number of companies, including large pharmaceutical companies and established biotechnology companies, that are pursuing similar therapeutic targets. Competition from companies developing therapies for RAS and PI3K mutations could impact market penetration and pricing.
• Uncertainty of Regulatory Approval [high — regulatory]: The process of obtaining regulatory approval for new drugs is lengthy, expensive, and uncertain. There is no guarantee that BridgeBio Oncology Therapeutics' product candidates will receive approval from regulatory authorities such as the FDA. The company's lead candidate, BBO-8520, is still in dose escalation, indicating a long path to potential approval.
• Potential Market Overhang from Selling Securityholders [medium — financial]: The registration of 63,054,549 shares of common stock for sale by selling securityholders, including 24,343,711 PIPE shares, could create a significant market overhang. If these shares are sold rapidly, it could depress the stock price, especially given the company's clinical-stage status.

Industry Context

BridgeBio Oncology Therapeutics operates in the highly competitive oncology therapeutics sector, focusing on genetically defined cancers driven by RAS and PI3K mutations. The industry is characterized by rapid innovation, significant R&D investment, and a complex regulatory pathway. Key trends include precision medicine, targeted therapies, and the increasing understanding of cancer genomics, which BridgeBio aims to leverage with its small molecule inhibitors.

Regulatory Implications

The company faces significant regulatory hurdles inherent in drug development. Successful navigation of FDA and other global regulatory agency requirements for clinical trials and marketing approval is paramount. Any delays, adverse findings in clinical trials, or failure to meet stringent efficacy and safety standards could prevent product commercialization.

What Investors Should Do

1. Monitor clinical trial progress and data releases for BBO-8520.
2. Assess the company's ability to secure future funding.
3. Evaluate the competitive landscape for RAS and PI3K inhibitors.
4. Consider the potential impact of the registered selling securityholder shares.

Key Dates

• 2025-08-11: Business Combination Closing — BridgeBio Oncology Therapeutics became a publicly traded company on Nasdaq under the ticker 'BBOT' following its business combination with Helix Acquisition Corp. II.
• 2025-02-28: PIPE Financing — The company raised capital through a private investment in public equity (PIPE) transaction, issuing 24,343,711 shares, which are now registered for sale.
• 2025-08-28: Stock Closing Price — The company's common stock closed at $9.45 per share on Nasdaq, providing a market valuation reference point.
• 2025-02-28: Business Combination Agreement — This date marks the initial agreement for the business combination, preceding the closing and subsequent public listing.
• H2 2025: Anticipated Data Release — BridgeBio Oncology Therapeutics expects to share initial interim data from the ONKORAS-101 trial for BBO-8520, which will be a key indicator of the drug candidate's progress.

Glossary

S-1 Filing

A registration statement filed with the U.S. Securities and Exchange Commission (SEC) by companies planning to offer securities to the public. It contains detailed information about the company's business, financial condition, and management. (This document provides the foundational information for investors to evaluate BridgeBio Oncology Therapeutics.)

PIPE Shares

Shares issued in a Private Investment in Public Equity. This is a way for public companies to raise capital by selling shares directly to institutional investors, often at a discount to the market price. (The 24,343,711 PIPE shares represent a significant portion of the registered shares for sale, impacting potential market supply.)

RAS and PI3K Mutations

Specific genetic mutations in the RAS and PI3K signaling pathways, which are frequently implicated in the development and progression of various cancers. (These mutations are the primary targets for BridgeBio Oncology Therapeutics' drug development pipeline.)

KRAS G12C Inhibitor

A type of drug designed to block the activity of a specific mutated form of the KRAS protein (G12C mutation), which is a common driver in certain cancers. (BBO-8520 is a KRAS G12C inhibitor, representing the company's lead product candidate.)

ONKORAS-101 Trial

The ongoing clinical trial for BridgeBio Oncology Therapeutics' lead candidate, BBO-8520, which is in the dose escalation phase for metastatic KRAS G12C mutant NSCLC. (The results of this trial are critical for the future development and potential approval of BBO-8520.)

Business Combination

A merger or acquisition transaction where two companies combine to form a new entity or one company acquires another. In this case, Helix Acquisition Corp. II combined with BridgeBio Oncology Therapeutics. (This transaction enabled BridgeBio Oncology Therapeutics to become a publicly traded company.)

Year-Over-Year Comparison

As this is an S-1 filing, it represents the initial public disclosure of BridgeBio Oncology Therapeutics' financial and operational status following its business combination. Therefore, a direct comparison to a prior filing is not applicable. Key metrics such as revenue, net income, and margins are not yet established as the company is pre-commercial. The filing primarily details the company's pipeline, strategy, and the structure of its public listing, including the significant number of shares registered for sale by existing securityholders.

Key Financial Figures

• $0.0001 — 4,549 shares of common stock, par value $0.0001 per share of BridgeBio Oncology Therape
• $1.02 — options at exercise prices ranging from $1.02 to $7.88 per share (the "Options"), iss
• $7.88 — t exercise prices ranging from $1.02 to $7.88 per share (the "Options"), issued to ce
• $9.45 — e closing price of our Common Stock was $9.45 per share. We are an "emerging growth

Filing Documents

• d67813ds1.htm (S-1) — 3891KB
• d67813dex51.htm (EX-5.1) — 9KB
• d67813dex1021.htm (EX-10.21) — 254KB
• d67813dex231.htm (EX-23.1) — 2KB
• d67813dex232.htm (EX-23.2) — 1KB
• d67813dexfilingfees.htm (EX-FILING FEES) — 18KB
• g67813g03v03.jpg (GRAPHIC) — 221KB
• g67813g06v01.jpg (GRAPHIC) — 215KB
• g67813g06v02.jpg (GRAPHIC) — 121KB
• g67813g07v07.jpg (GRAPHIC) — 229KB
• g67813g0828160124084.jpg (GRAPHIC) — 3KB
• g67813g08v01.jpg (GRAPHIC) — 183KB
• g67813g08v02.jpg (GRAPHIC) — 184KB
• g67813g10f11.jpg (GRAPHIC) — 199KB
• g67813g10f13.jpg (GRAPHIC) — 192KB
• g67813g10f14.jpg (GRAPHIC) — 200KB
• g67813g10g10.jpg (GRAPHIC) — 147KB
• g67813g10g11.jpg (GRAPHIC) — 185KB
• g67813g10g12.jpg (GRAPHIC) — 242KB
• g67813g10g13.jpg (GRAPHIC) — 202KB
• g67813g10g14.jpg (GRAPHIC) — 216KB
• g67813g10g15.jpg (GRAPHIC) — 181KB
• g67813g10g16.jpg (GRAPHIC) — 178KB
• g67813g10g90.jpg (GRAPHIC) — 205KB
• g67813g10g91.jpg (GRAPHIC) — 165KB
• g67813g17g01.jpg (GRAPHIC) — 189KB
• g67813g17g02.jpg (GRAPHIC) — 186KB
• g67813g18g01.jpg (GRAPHIC) — 212KB
• g67813g18g02.jpg (GRAPHIC) — 202KB
• g67813g19g01.jpg (GRAPHIC) — 207KB
• 0001193125-25-192760.txt ( ) — 19464KB
• bbot-20250630.xsd (EX-101.SCH) — 738KB
• d67813ds1_htm.xml (XML) — 820KB
• d67813dexfilingfees_htm.xml (XML) — 5KB

USE OF PROCEEDS

USE OF PROCEEDS 82 DETERMINATION OF OFFERING PRICE 83 DIVIDEND POLICY 84 MARKET INFORMATION 85 SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS 86 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION 87

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 144 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 162 MANAGEMENT 167

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 174

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 194 SECURITIES ACT RESTRICTIONS ON RESALE OF SECURITIES 198 PRINCIPAL STOCKHOLDERS 200 SELLING SECURITYHOLDERS 202 PLAN OF DISTRIBUTION 211 LEGAL MATTERS 216 EXPERTS 216 WHERE YOU CAN FIND MORE INFORMATION 217 INDEX TO FINANCIAL STATEMENTS F-1 Table of Contents MARKET AND INDUSTRY DATA This prospectus contains assumptions and information concerning our industry, our business, and the market for our services and solutions, including our market position, our general expectations of our market opportunity, and size and growth rates of the markets in which we participate, that are based on industry publications, surveys, and reports that have been prepared by independent third parties. This information involves a number of assumptions and limitations, and industry in which we operate is subject to a high degree of uncertainty and risk. As a result, the estimates and market and industry information provided in this prospectus are subject to change based on various factors, including those described in " Cautionary Note Regarding Forward-Looking Statements " and " Risk Factors — Risks Related to BBOT's Business " and elsewhere in this prospectus. Industry publications, research, studies and forecasts generally state that the information they contain has been obtained from sources believed to be reliable, but that the accuracy and completeness of such information is not guaranteed. Although we have not independently verified the accuracy or completeness of third-party information, we believe the industry and market information included elsewhere in this prospectus is reliable. Forecasts and other forward-looking information obtained from these sources are subject to the same qualifications and uncertainties as the other forward-looking statements in this prospectus. These forecasts and forward-looking information are subject to uncertainty and risk due to a variety of factors, including those described

View Full Filing

View this S-1 filing on SEC EDGAR